1 / 10

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized disc

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Authors: Hussain M. et al, ASCO 2011 Abstract: 4516 Reviewed by: Dr. Lori Wood Date posted: June 2011.

liko
Download Presentation

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized disc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Authors: Hussain M. et al, ASCO 2011 Abstract: 4516 Reviewed by: Dr. Lori Wood Date posted: June 2011

  2. Thank you for downloading this update. Please feel free to use it for educational purposes. Please acknowledge OncologyEducation.ca and Dr. Lori Wood when using these slides.

  3. New agents for metastatic CRPCa are needed Cabozantinib (XL184) An oral TKI of MET and VEGFR MET drives tumor cell invasion and metastases MET and VEGFR synergize to promote angiogenesis In prostate cancer Pre-clinically – ADT  MET expression MET  with progression and metastases STUDY RATIONALE

  4. STUDY DESIGN Phase III Randomized Discontinuation Trial • Metastatic CRPCa patients: • - 0-1 prior chemotherapy • - all received Cabozantinib • 100 mg p.o. qd x 12 weeks • Primary objectives: • - lead-in stage – RECIST RR • - randomized stage - PFS • Planned n=200; accrual • discontinued after n=171 due • to better than expected • results PR/CR Continue Continue (n=14) R SD Placebo (n=17) PD Stop

  5. RESULTS At 12 Weeks PR/CR Open Label Extension n=79 (46%) SD Randomized n=31 (18%) Off Study n=61 (36%) PD = 16% AE = 15% Death = 1% Other = 4%

  6. RESULTS • Lead-in stage • 68% overall objective disease control at week 12 • 74% measurable soft tissue disease regression • 76% complete or partial bone scan resolution • 67% improvement in pain • PSA changes did not correlate with radiological response • Randomization stage • PFS = 21 weeks vs. 6 weeks

  7. RESULTS Best Overall Effect on Bone Scan (n = 108) • CR = 19% • PR = 56% • SD = 21% • PD = 3%

  8. TOXICITY • Grade  3 adverse events in lead-in stage • Fatigue = 16% • Thrombosis = 7% • Hypertension = 6% • Hand/Foot = 6% • Anorexia = 5% • GI Perforation = 2% • 51% of patients had  dose reduction • 1 death potentially 2 treatment (unexplained death)

  9. STUDY COMMENTARY • Cabozantinib is a first in class TKI to act on both MET and VEGFR. • This phase II randomized discontinuation study with Cabozantinib showed very impressive results, especially bone scan and pain improvement. • Will the endpoints looked at (bone scan and pain improvement) translate into an improvement in overall survival? • This drug is in many other clinical trials right now with prostate cancer patients and no doubt we will hear a lot more about it.

  10. Very exciting drug Would be great to participate in clinical trials with this drug BOTTOM-LINE FOR CANADIAN MEDICAL ONCOLOGISTS

More Related